Key Highlights

  • Third quarter Revenue rose 25.2% to USD 24.9 million from USD 19.9 million, and nine-month revenue increased 19.4% to USD 68.0 million.
  • Interventional Dry Eye revenue reached USD 3.9 million versus USD 0.2 million a year ago, after two Medicare contractors set fee schedules for the TearCare procedure code.
  • Sight Sciences (NASDAQ:SGHT) cut its quarterly net loss to USD 6.8 million, or USD 0.12 per share, from USD 8.2 million, or USD 0.16, as research spending fell 19.3% and Gross Profit climbed to USD 21.4 million.
  • Cash and cash equivalents were USD 77.4 million on September 30, 2026, against a term Loan balance of USD 40.0 million, and nine-month operating cash use narrowed to USD 15.1 million from USD 27.9 million a year earlier.

TearCare Reimbursement Reshapes the Revenue Mix

Sight Sciences (NASDAQ:SGHT) filed its Quarterly Report on November 4, 2026. Revenue was USD 24.9 million, up USD 5.0 million. Interventional Glaucoma, which sells the OMNI Surgical System and SION instrument, grew 6.7% to USD 21.0 million on more OMNI units and higher average selling prices. Interventional Dry Eye, the TearCare business, grew to USD 3.9 million on more single-use SmartLids and higher prices. The filing links that growth to fee schedules for CPT code 0563T set by two Medicare Administrative Contractors in the fourth quarter of 2025. The dry eye segment is now 15.6% of revenue, from 0.9%, and nine-month dry eye revenue was USD 7.9 million against USD 0.9 million. Over 90% of revenue came from US customers.

Gross Margin Dips While the Operating Loss Narrows

Gross profit rose 24.6% to USD 21.4 million, but total gross margin eased to 85.9% from 86.4% because TearCare carries a lower 79.0% margin than glaucoma at 87.2%. Research and Development expense fell to USD 2.7 million from USD 3.4 million, while selling, general and administrative expense rose 14.2% to USD 24.8 million. The loss from operations narrowed 22.5% to USD 6.1 million. Nine-month net loss was USD 24.2 million against USD 34.3 million, or USD 0.44 per share against USD 0.66. Investment income fell to USD 0.7 million from USD 1.0 million, while interest expense stayed near USD 1.3 million.

Loan Balance, Third-Party Manufacturing and Remaining Losses

The company has an accumulated Deficit of USD 409.0 million and expects to keep reporting net losses for at least several years. It says its cash should fund operations for at least the next 12 months. The term loan with Hercules Capital was USD 40.0 million, plus a USD 2.4 million final payment due at maturity. All products are made by third-party manufacturers, many single source suppliers, so Supply disruption is a risk. Demand also tends to be lower in the third quarter because of eyecare provider vacations. The filing gave no guidance and no stock price information, so how investors will read the quarter cannot be assessed from it.

Where Things Stand

Growth looks likely to continue only if TearCare demand holds, because most of the quarter's expansion came from that small base. Sight Sciences (NASDAQ:SGHT) still grew glaucoma sales and narrowed its loss, but it remains unprofitable and carries term debt. Next markers are further reimbursement coverage for TearCare in other jurisdictions, glaucoma unit and pricing trends, spending discipline and cash use in the fourth quarter. Net losses are expected to continue, and the company may seek more Debt or Equity Financing to fund growth, which could dilute holders.